Taysha Gene Therapies Price to Sales Ratio 2020-2024 | TSHA
Historical PS ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The current P/S ratio for Taysha Gene Therapies as of November 01, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Taysha Gene Therapies P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-11-01 |
1.53 |
|
17.32 |
| 2024-06-30 |
2.24 |
$0.09 |
25.36 |
| 2024-03-31 |
2.87 |
$0.12 |
23.75 |
| 2023-12-31 |
1.77 |
$0.18 |
9.81 |
| 2023-09-30 |
3.16 |
$0.15 |
21.15 |
| 2023-06-30 |
0.66 |
$0.11 |
5.92 |
| 2023-03-31 |
0.80 |
$0.07 |
10.72 |
| 2022-12-31 |
2.26 |
0 |
0.00 |
| 2022-09-30 |
1.93 |
0 |
0.00 |
| 2022-06-30 |
3.72 |
0 |
0.00 |
| 2022-03-31 |
6.52 |
0 |
0.00 |
| 2021-12-31 |
11.65 |
0 |
0.00 |
| 2021-09-30 |
18.62 |
0 |
0.00 |
| 2021-06-30 |
21.20 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.314B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
